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E-mail: aurora.martinez@uib.noMutations in hydroxymethylbilane synthase (HMBS) cause
acute intermittent porphyria (AIP), an autosomal dominant
disease where typically only one HMBS allele is mutated. In
AIP, the accumulation of porphyrin precursors triggers life-
threatening neurovisceral attacks and at long-term, entails an
increased risk of hepatocellular carcinoma, kidney failure,
and hypertension. Today, the only cure is liver transplantation,
and a need for effective mechanism-based therapies, such as
pharmacological chaperones, is prevailing. These are small
molecules that specifically stabilize a target protein. They
may be developed into an oral treatment, which could work
curatively during acute attacks, but also prophylactically in
asymptomatic HMBS mutant carriers. With the use of a
10,000 compound library, we identified four binders that
further increased the initially very high thermal stability of
wild-type HMBS and protected the enzyme from trypsin diges-
tion. The best hit and a selected analog increased steady-state
levels and total HMBS activity in human hepatoma cells over-
expressing HMBS, and in an Hmbs-deficient mouse model
with a low-expressed wild-type-like allele, compared to un-
treated controls. Moreover, the concentration of porphyrin
precursors decreased in liver of mice treated with the best hit.
Our findings demonstrate the great potential of these hits for
the development of a pharmacological chaperone-based correc-
tive treatment of AIP by enhancing wild-type HMBS function
independently of the patients’ specific mutation.
INTRODUCTION
Acute intermittent porphyria (AIP; OMIM: 176000) is an inborn error
of metabolism caused by mutations in the third enzyme of the heme
synthesis pathway, i.e., hydroxymethylbilane synthase (HMBS; EC
2.5.1.61). To date, more than 420 different mutations in the HMBS
gene have been reported (available at http://www.hgmd.cf.ac.uk/ac/
gene.php?gene=HMBS), including both catalytically and/or conforma-
tionally deleterious mutations. The prevalence of AIP is about 1 in
20,000–100,000, depending on the ethnic group.1,2 However, the over-
all penetrance is 0.5%–1% in the general population and 10%–20%
within families.3,4 Factors, such as hormonal changes, low carbohy-Molec
This is an open access article under the CC BY-NC-drate intake, alcohol, or porphyrinogenic drugs, activate the expression
of hepatic d-aminolevulinic acid (ALA) synthase 1 (ALAS1). Elevated
levels of ALAS1, together with diminishedHMBS activity, lead to accu-
mulation of the heme precursors ALA and porphobilinogen (PBG).
PBG and in particular ALA are believed to be toxic metabolites related
to the neuropathy of the disease and to trigger the acute attacks.5 In
addition, PBG at high concentrations may further decrease HMBS ac-
tivity.6,7 The attacks are unspecific with common symptoms, such as
abdominal pain, nausea, tachycardia, and hypertension, in addition
to various neurological and psychiatric symptoms.1 More severe symp-
toms, such as acute psychosis and potentially life-threatening symp-
toms—paralysis and coma—may also occur.8,9 AIP patients have a
higher risk of developing hepatocellular carcinoma, hypertension,
and kidney failure.10,11
Intravenous administration of human hemin is the established spe-
cific treatment for severe and recurrent AIP attacks, providing exog-
enous heme that downregulates ALAS1 expression.12 However,
repeated therapy can be associated with reduced efficacy2 but may
also give a chronic activation of heme oxygenase 1 expression that
will trigger ALAS1 and subsequently recurrent attacks.13 Liver trans-
plantation is today the only curative alternative for chronically ill
patients.14 Although several therapeutic options are under investiga-
tion,15–18 there is still a need for effective mechanism-based pharma-
cotherapies, as this would provide a noninvasive, oral treatment that
could possibly work prophylactically,19 as well as a specific medica-
tion during an acute attack.
Pharmacological chaperones (PCs) are defined as small molecular
weight compounds that specifically target and interact with unstable
and incorrectly folded proteins. PC binding stabilizes the target pro-
tein, protecting it from early degradation, thus increasing its half-lifeular Therapy Vol. 28 No 2 February 2020 ª 2019 The Authors. 677
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Screening and Validation of Stabilizing Hit Compounds for HMBS
(A) Representative differential scanning fluorimetry (DSF) profiles for HMBS in the
absence and presence of hit compounds. The thermal upshift values (DTm) for the
compounds are determined from the midpoint denaturation temperatures (Tm at
y = 0.5) compared to the control sample with 2% DMSO (Tm = 76.6 ± 0.5
C). The
profiles represent recombinant WT-HMBS incubated with the 0.04-mg/mL
compound (average concentration 122 mM) in 2% DMSO (red, C5; blue, C6; see
the formulas in Table 2) and the control sample without compound, with 2%
DMSO (dotted gray). (B) Protection of hit compounds against limited tryptic
proteolysis of WT-HMBS. Top: SDS-PAGE showing the effect of the indicated
compounds (84 mM and 2% DMSO) on HMBS trypsination. std, low molecular
weight standards; control n.t., no trypsin added; control DMSO, HMBS with 2%
DMSO and trypsin. Bottom: quantification of the lowest 31.5-kDa band relative to
the full-length HMBS at 42.5 kDa. *p < 0.05 and **p < 0.01 for differences
compared to the DMSO control, calculated by unpaired two-tailed t test. Data are
presented as mean ± SD.
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strated as a potential treatment for protein misfolding diseases, such
as cystic fibrosis,23 phenylketonuria,24 lysosomal storage disorders,25
and congenital erythropoietic porphyria.26 Residual enzymatic activ-
ity is required for the PCs to enhance the activity of conformational
mutations that result in an unstable and misfolded enzyme. The
focus for the PC discovery in the above-mentioned recessive genetic
diseases has been the development of PCs targeting either one partic-
ularly commonmutation in the target protein23 or a range of respon-
sive mutations.25 However, AIP presents as a model disorder for
autosomal dominantly inherited diseases, where fully functional
wild-type (WT) HMBS is expressed from only one allele and pro-
vides 50% of normal enzymatic activity. This is seemingly enough
to maintain normal cellular metabolism,27 although once the heme
synthesis is challenged, the amount of functional gene product is un-
able to compensate for the allele that holds the HMBS mutation.
Relevantly for AIP and other inherited disorders with haploinsuffi-
ciency, PCs have demonstrated value in increasing the stability of
WT enzymes in vitro and in vivo.24,28–30 In the case of AIP, however,
possible porphyrogenicity of a future drug must also be taken into
account, as the list of drugs that may cause an acute crisis is very
large.31,32
In this work, we present the discovery and identification of potential
PCs to treat AIP. We have focused on the effect of candidate mole-
cules selected by high-throughput screening and validated in vitro
by analyzing their effect on the conformational and kinetic stability
of purified recombinantWT-HMBS. Furthermore, we evaluated their
PC potential in human hepatoma HepG2 cells overexpressing WT-
HMBS and in vivo using an Hmbs-deficient T1/T2/ mouse model.
The Hmbs-deficient mice exhibits 30% of normal hepatic activity
and is compound heterozygous of one null allele and one low-ex-
pressed normal allele.33 Our findings reveal hit compounds that sta-
bilize WT-HMBS and show a large potential in the development of a
PC therapy for AIP, independent of the patients’ mutation, with the
possibility of being both curative for acute attacks and having a pro-
phylactic effect to impede recurrent acute attacks.
RESULTS
Selection of Potential Pharmacological Chaperones
The effect of 10,000 compounds on the thermostability of recombi-
nant WT-HMBS was investigated using differential scanning fluo-
rimetry (DSF). The thermal melting profile of HMBS, studied by
DSF and other methods, shows a major transition with a half-dena-
turation temperature (Tm) of 74C,34 which is slightly increased
in the presence of 2% DMSO (Tm = 76.6 ± 0.5C) (Figure 1A, gray
dotted line). This value, where the temperature of the normalized
fluorescence curves crossed y = 0.5, was used as a reference to deter-
mine the shifts in Tm in the presence of compound compared to the
DMSO control (DTm = Tm(compound hit)  Tm(DMSO control)).
Positive shifts indicate ligand binding and protein stabilization.35
The first derivative (dF/dT; Figure 1A, bottom) was used for visuali-
zation of the complexity and qualitative inspection of the transitions.
Despite the remarkable conformational stability of HMBS, which














Control – 1.00 1.00 –
C4 1.6 1.04 ± 0.05 0.92 ± 0.07** ND
C5e 2.1 1.05 ± 0.02 1.04 ± 0.05 +*
C6e 1.6 0.98 ± 0.06 1.01 ± 0.06 ++**
C8 4.5 1.01 ± 0.03 0.92 ± 0.05** ND
C9 3.8 0.98 ± 0.03 1.04 ± 0.07 +/
C11e 1.6 1.00 ± 0.03 1.01 ± 0.04 +
C12 2.2 1.07 ± 0.05 0.94 ± 0.09 +/
C15 1.5 1.00 ± 0.02 0.91 ± 0.07* ND
C16 2.0 1.04 ± 0.04 0.91 ± 0.03*** ND
C17e 2.3 1.09 ± 0.05 1.07 ± 0.04 +*
C19 2.0 1.04 ± 0.02 0.95 ± 0.06 +/
C23 1.6 0.92 ± 0.05** 0.96 ± 0.06* ND
C24 2.3 1.08 ± 0.03 0.81 ± 0.06**** ND
The effect of the 13 primary hit compounds on the Tm of HMBS measured by DSF,
enzymatic activity, and limited tryptic proteolysis of the enzyme. *p < 0.05, **p <
0.01, ***p < 0.001, and ****p < 0.0001 for significance compared with the DMSO control
sample, calculated by unpaired two-tailed t test. Data are presented as mean ± SD.
aThe thermal upshift values (DTm) monitored by DSF. The average compound concen-
tration in DSF screening was 122 mM (2% DMSO).
bActivity assay performed at standard conditions, with 100 mM PBG at 37C, 84 mM
compound, and 2% DMSO, which was added in all controls.
cAssay, including preincubation of HMBS with compound at 70C, and subsequent
standard activity assay, with 100 mM PBG at 37C, 84 mM compound, and 2% DMSO.
d+/, ±2%; +, >4%; ++, 10% remaining full-length HMBS relative to DMSO; ND, not
determined; see main text and Figure 1B for details.
eHit compounds selected for cell studies.
Table 2. Hit Compounds Selected for Validation
ID Structure KM (PBG)
a (mM) Vmax
a (nmol/min/mg)
Control – 86 ± 5 61 ± 2
C5 81 ± 5 55 ± 1**
C6 69 ± 4* 56 ± 1*
C11 77 ± 5 59 ± 1
C17 81 ± 2 58 ± 2
Chemical structure of the four hit compounds selected for cellular studies and steady-
state enzyme kinetic parameters of HMBS in the presence of the compounds. *p <
0.05 and **p < 0.01 for significant difference compared with the values for the control
sample (with 2% DMSO), calculated by unpaired two-tailed t test. Data are presented as
mean ± SD.
aEffect of the compounds on the enzyme kinetic parameters for HMBS activity,
measured at fixed compound concentration (84 mM in 2% DMSO) and variable PBG
(0–1 mM) at 37C, and fitted to Michaelis-Menten kinetics.
www.moleculartherapy.orgpresents a significantly higher Tm than the customary value for the
majority of mammalian proteins (Tm z55C),
36 we discovered
several compounds causing positive DTm values. 64 compounds sta-
bilized HMBS R 1.5C at 0.04 mg/mL (80–167 mM) (see Figure 1A
for representative stabilizing compounds) and were further filtered
against pan assay interference compounds.37 The remaining 22 com-
pounds were analyzed by concentration-dependent DSF, with con-
centrations up to 84–167 mM, to corroborate specific binding (data
not shown), and 13 compounds were assigned as primary hits and
selected for further analyses (Tables 1 and S1). These compounds
did not have a clear structural resemblance.
Validation of Hit Compounds
We investigated the effect of the 13-hit compounds on the enzyme
activity and conformational stability of HMBS. HMBS activity of
the recombinant enzyme was measured in the absence and presence
of compounds (at 84 mM) at standard conditions (37C) and consid-
ering the high thermal stability of WT-HMBS, also after preincuba-
tion at 70C for 20 min. The results are presented in Table 1. Com-
pounds that displayed an inhibitory effect of 8%–20% at one or
both conditions were eliminated, leaving seven noninhibitory poten-tial hits (compounds [C] 5, 6, 9, 11, 12, 17, and 19). To ensure a reli-
able selection of hit compounds for testing in cells and in vivo, limited
tryptic proteolysis was applied to select the hit compounds with the
greatest capacity to increase the conformational stability of HMBS.
Proteolysis of WT-HMBS (DMSO control) provided three major
bands with relative content 34.5 ± 0.3%, 14.7 ± 0.8%, and 50.9 ±
0.5% (mean ± SD) at the selected conditions, corresponding to re-
maining full-length HMBS (42.5 kDa), and two fragments of
41.0 kDa and 31.5 kDa, respectively (Figure 1B). Protection
against proteolysis was obtained for hit compounds C5, C6, C11,
and C17, notably for C6, which provided a higher proportion of
full-length HMBS after tryptic treatment compared with the DMSO
control (Figure 1B). The chemical structures of these compounds
are shown in Table 2, together with their effect (at 84 mM) on the
steady-state enzyme kinetic parameters of HMBS. A decreased
Vmax but a similar KM (PBG) was obtained in the presence of C5, indi-
cating a noncompetitive, inhibitory effect, but the effects of C6, which
reduced both KM and Vmax, agreed with mixed/uncompetitive inhibi-
tion. Neither C11 nor C17 caused any changes in KM or Vmax. C5, C6,
C11, and C17 were selected for further validation in cells.The Effect of Hit Compounds in HepG2 Cells
The stabilizingandpotential PCeffect of the selectedhit compoundsC5,
C6, C11, and C17 was investigated in HepG2 cells overexpressing
HMBS by analyzing the steady-state levels of the enzyme as a function
of compound concentration. Quantitative immunoblotting revealed an
increasing amount ofHMBS forC6 (Figure 2A)butnot forC5,C11, and
C17 (Figure S1).Moreover, the addition of C11 andC17 toHepG2 cellsMolecular Therapy Vol. 28 No 2 February 2020 679
Figure 2. Effect of the Hit Compounds C6 and Its
Analog C6-3 on HMBS in HepG2 Cells and
Concentration-Dependent Surface Plasmon
Resonance
(A and B) Western blotting and immunoquantification of the
relative amount of HMBS in cell lysates from WT-HMBS
stably transfected HepG2 cells treated with either C6 (A) or
its analog C6-3 (B; see molecular structure in Table 3 and
main text thereafter) at the indicated concentrations. DMSO
(2%) was included in all samples. Representative blots are
shown, and the histograms below represent the quantifi-
cation of the relative HMBS levels (n = 3) using GAPDH as
the protein loading control. Concentration-dependent
binding of C6 (C) and C6-3 (D) to HMBSmeasured by SPR.
The half-maximal binding (S0.5) values were 83 ± 7 mM for
C6, obtained by subsequent Octet measurements (C,
inset), and 63 ± 3 mM for C6-3, obtained from the SPR
binding isotherm (D). Data are presented as mean ± SD.
Molecular Therapyseemed to have adverse effects, as we observed severe morphological
changes and cell death already at low compound concentrations. These
two compounds were therefore excluded from further studies.The Initial Effect of Hit Compounds on ALA and PBG Excretion in
Hmbs-Deficient Mice
In view of the promising results withC6 (5-[(2-chlorophenyl)methyl]-
2-hydroxy-3-nitrobenzaldehyde) as anHMBS stabilizer in vitro and in
cells (Figures 1 and 2A; Table 1), we continued by testing its effect in a
preliminary trial (Trial T1/T2-A) using the compound heterozygous
Hmbs-deficient T1/T2/ mouse model for AIP. This model allows
monitoring the increased level of precursors ALA and PBG in urine
after phenobarbital induction, which stimulates the heme synthesis.
C5 (2-methoxy-N-[(phenylcarbamothioyl)amino]acetamide) was
also included in the trial due to its good stabilizing effect in vitro (Fig-
ure 1; Table 1). A schematic overview of the mice trials can be seen in
Figure S2. In trial T1/T2-A, two groups of six mice each were given
10 mg/kg/day of either C5 or C6 for 12 days. A control group of six
mice, treated with only DMSO, was also included. All mice were given
phenobarbital (Gardenal) during the last 3 days of the study. No680 Molecular Therapy Vol. 28 No 2 February 2020apparent toxicity in the treatedmice was detected,
as assessed by normal health and behavior during
the 12-day study and organ appearances after sac-
rifice. As previously reported,Hmbs-deficient T1/
T2/mice do not show elevated excretion of uri-
nary ALA and PBG until induction of biochem-
ical acute attacks,33 and indeed a rapid increase
in both urinary ALA and PBG was seen for the
control mice by day 11 and even higher by day
12, following the phenobarbital administration
(Figures S3A and S3B, gray bars). The treatment
with 10 mg/kg/day did not cause any significant
change in HMBS protein levels or activity in
either erythrocytes or liver, compared to the non-treatedHmbs-deficient mice (data not shown). However, a decreasing
tendency in urinary levels of ALA, but not PBG, was observed for both
C6 and C5 treatment by day 12 (Figure S3B) compared to nontreated
mice, suggesting that a higher compound concentration may result in
an increasedmetabolite level correction. Similarly, compound analogs
with higher affinity might increase the effect due to a more efficient
dose-dependent effect in vivo.
Identification of Hit Compound Analogs
Through the implementation of a compound similarity search of the
best hit C6, we aimed to identify analogs that corroborated or even
improved the stabilizing effects on HMBS. We obtained three close
analogs with a chemical similarity of >70% to the query C6, calculated
using the Tanimoto coefficient for 2-dimensional (2D) similarity
searching38,39 (Table 3). The analogs were tested on recombinant
WT-HMBS using DSF and tryptic proteolysis, and analog C6-3
((4-chloro-3-nitrophenyl)(phenyl)methanone) (Table 3) was selected
for further studies. In cells, C6-3 increased the HMBS protein levels
(Figure 2B), and enzyme kinetic analyses showed a weak noncompet-
itive inhibition (Table 3). C6-3 was therefore selected for further
analysis.
Table 3. Compound Analogs of C6
ID IUPAC Name and Structure MW DTm
a (C) Protection against Tryptic Proteolysisb KM (PBG)
c (mM) Vmax
c (nmol/min/mg)
Control – – – – 86 ± 5 61 ± 2
C6-1
5-benzyl-2-hydroxy-3-nitrobenzaldehyde




293.7 4.7 +/ – –
C6-3
(4-chloro-3-nitrophenyl)(phenyl)methanone
261.66 4.9 +* 84 ± 8 54 ± 2**
The analogs of C6 were selected from the compound similarity search calculated using the Tanimoto coefficient. The Tanimoto coefficient is used to calculate the 2D similarity between
sets of chemical structures.38 The effect of the analogs on both the DTm measured by DSF and on the limited tryptic proteolysis of HMBS was determined. Steady-state enzymatic
kinetic parameters of HMBS in the presence of analogs were only determined for the analog that protected toward tryptic proteolysis (C6-3). *p < 0.05 and **p < 0.01 for significant
difference compared with the values for the control sample (with 2%DMSO), calculated by unpaired two-tailed t test. Data are presented as mean ± SD. IUPAC, International Union of
Pure and Applied Chemistry.
aThe thermal upshift values (DTm) monitored by DSF. The average compound concentration in DSF screening was 122 mM (2% DMSO).
b+/, ±2%; +, >4%.
cEffect of the compounds on the enzyme kinetic parameters for HMBS activity, measured at fixed compound concentration (84 mM with 2% DMSO) and variable PBG (0–1 mM) at
37C, and fitted to Michaelis-Menten kinetics.
www.moleculartherapy.orgThe Binding of the Hit Compounds C6 and C6-3 to HMBS
The binding of C6 andC6-3 to HMBSwas analyzed by surface plasmon
resonance (SPR), measuring the response units from the compound
concentration-dependent, steady-state binding response, and analyzed
assuminga1:1bindingmodel (Figures2Cand2D).C6showed someun-
specific binding by SPR, and an accurate concentration of compound at
half-maximal binding (S0.5) could not be obtained (Figures 2C, S4A, and
S4B). The binding of C6 to HMBS was therefore also analyzed with the
Octet RED96 system with super streptavidin (SSA) biosensors in which
data analysis usingdouble reference subtractionaccounts fornonspecific
binding and minimizes the well-based and sensor variability. For the
loadingof the sensors, the proteinneeded tobe biotinylated, butno alter-
ation for the buffer conditions was required. The analyses with Octet
provided an S0.5 value of 83 ± 7 mM for C6, obtained by fitting the
data to a sigmoidal binding isotherm with saturable concentration
dependence (Figure 2C, inset). For C6-3, SPR allowed themeasurement
of good concentration-dependent binding data, also with a sigmoidal
binding curve, providing an S0.5 value of 63 ± 3 mM (Figure 2D).
Whereas C6-3 (andC5) showed a veryweak noncompetitive inhibition,
only affecting the Vmax (Table 3), C6 showed uncompetitive inhibition
and a decrease in both KM and Vmax (Table 2), indicating a preferential
binding to the enzyme-substrate complex during catalysis rather than to
the enzymealone. It is difficult topredict binding sites fornon-active site
ligands, but uncompetitive inhibition customarily occurs by binding
close to (still outside) the active site.40With the use of the pocket finder
tool fpocket to identify binding sites adequate to accommodate stabiliz-
ing small-molecule compounds,41 the structure of the human HMBSholoenzyme (PDB: 3ECR) revealed two relevant binding pockets other
than the active site pocket (Figure 3A). However, computational pro-
tein-ligand docking suggested a favorable binding mode of both C6
(and C6-3; not shown) in only one of these pockets, close to the active
site (Figure 3B).Consequentdocking to the holoenzymeprovided a top-
score binding mode of C6 in which the hydroxyl and aldehyde oxygens
of C6 interact with the guanidine group of Arg195, facilitating two
hydrogen bonds, whereas the more hydrophobic part can interact
with Leu238 and Val38 (Figure 3C). On the other hand, for C6-3, the
oxygens that interact with Arg195 via hydrogen bonds are those in
the nitro group (Figure 3D). TheX-ray structure of an enzyme interme-
diate captured in the ES2 state, with two PBG substrates bound to the
covalently linked dipyrromethane (DPM) cofactor (PDB: 5M6R), al-
lowed the prediction of the interaction of the PC candidates with inter-
mediate states of HMBS other than the holoenzyme.42Nevertheless, the
analysis of this ES2-state structure revealed overlapping binding pockets
as in the holoenzyme (Figures S5A and S5B). Subsequent docking to the
ES2-state structure showedpotential dockingmodes for the compounds
with similar docking scores as for the holoenzyme-docked structures,
with possible interactions with Val38 and Leu238.Hit Compound C6 and Analog C6-3 Decrease ALA and PBG
Excretion in Hmbs-Deficient Mice
In a second animal trial usingHmbs-deficient T1/T2/ mice, denoted
trial T1/T2-B, we further investigated the PC potential of C5, C6, and
C6-3 at higher concentration (20 mg/kg/day) than in trial T1/T2-A.
The experimental setup was otherwise identical (Figure S2), withMolecular Therapy Vol. 28 No 2 February 2020 681
Figure 3. The Interaction of C6 and C6-3 with HMBS
(A) Potential binding pockets large enough to accommo-
date small-molecule compounds in HMBS. The structure of
HMBS in the holoenzyme state (PDB: 3ECR) is shown in
cartoon representation with the pockets (1 and 2) in pink
spheres and cyan surface representation. The DPM
cofactor is shown in purple and red spheres. (B) Top-score
docked mode for C6, obtained for site 2 (blue sticks); see
text for details. This pocket also scored highest for docking
of C6-3. (C and D) Detailed view of the top-score docking
mode of C6 (blue; C) and C6-3 (green; D) interacting with
Arg195 in HMBS (PDB: 3ECR). In both panels, the DPM
cofactor is located in the background, and Arg195, Val38,
and Leu238 are denoted.
Molecular Therapyn = 6 in each treatment group and a control group (n = 6) receiving
DMSO instead of compound. C5 was again included in the trial due
to the overall good in vitro effects (Figure 1; Tables 1 and 2). The effect
of compounds was, as in trial T1/T2-A, monitored by themeasurement
of urinary excretion of ALA and PBG. C5 did not perform as a potential
PC of HMBS, as seen by the increase in ALA and PBG excretion by day
12 when mice were treated at 20 mg/kg/day of this compound,
compared with the mice treated with a lower dose (Figures S3A and
S3B) and to the controls (Figures 4Aand4B).This effect could be caused
either by a possible porphyrinogenic effect31 or by a larger inhibitory ef-
fect in vivo than predicted in vitro. On the other hand, bothC6andC6-3
reduced the urinary ALA and PBG excretion and the latter to almost
one-half of the value in the control group (Figures 4A and 4B). Further-
more, quantitative immunoblotting of liver tissue revealed an increase
in steady-state levels of HMBS in the presence of all three compounds,
with a significant increase only for C6 and C6-3 (Figure 4C). C5 was
thus not included in further analyses of the effect of the compounds
on hepatic HMBS activity and metabolite levels.
The effect of treatment with C6 and C6-3 on hepatic HMBS activity
was measured in mice liver homogenates, and treatment with either
hit compound resulted in significantly increased enzyme activity in
the liver samples compared to the control group (Figure 4D). Further-
more, the relative concentrations of ALA and PBG were also deter-
mined in liver extracts, which were found to be decreased for the
mice treated with C6 (p < 0.05 and p = 0.053, respectively, compared
with control mice; Figures 4E and 4F).
DISCUSSION
Current AIP therapy investigations target the disease at a genetic level,
including HMBS gene delivery, as well as RNAi therapy to decrease682 Molecular Therapy Vol. 28 No 2 February 2020ALAS1 expression.16–18 The first HMBS gene-de-
livery phase I clinical trial demonstrated that gene
vector administration was safe, but a metabolic
correction was not achieved at the doses tested.43
Furthermore, heme is a central cofactor involved
in diverse metabolic processes, and ALAS1 is a
highly regulated enzyme,44 and downstream
effects, such as energetic metabolism and long-term heme depletion, may be affected by RNAi therapy.16,45 In this
work, we aim to target AIP at the protein level by developing a PC-
based therapy. By achieving a structural equilibrium toward more
native-like conformations, the consequences of misfolding mutations
may be prevented.46 We have, however, targeted the stabilization of
the WT protein since most AIP patients have HMBS expression
from one normal HMBS allele. We performed an experimental
screening for compounds that stabilized recombinant WT-HMBS
during thermal denaturation.47,48 Despite the high stability of
HMBS,34 we identified compounds that further stabilizedWT-HMBS.
We selected C5, C6, and an analog of the latter (C6-3) for in vivo
studies based on a combination of in vitro and cell experiments that
identified compounds that could increase the conformation stability
and protect the enzyme activity. Furthermore, careful enzyme kinetic
analysis with purified HMBS revealed weak inhibitory effects for these
compounds. However, weak inhibitors have been shown to be good
stabilizing PCs and activity enhancers in vivo.49,50 For C6, the results
were particularly promising during the entire drug-discovery protocol,
as it increased the steady-state levels of HMBS in cell studies (Fig-
ure 2A) and demonstrated potential as PCs in an animal trial at
20 mg/kg/day (Figure 4). We have previously shown that HMBS,
which presents as a very stable enzyme as isolated (Figure 1A), loses
conformational stability during catalysis or binding of the substrate.34
Since both the inhibitorymechanism and docking of C6 andC6-3 sup-
port their binding to the substrate-enzyme complexes, the stabilizing
effect of these compounds is expected to be even more relevant in cells
and in vivo where the substrate is continuously available.
Accumulation of the precursors ALA and PBG plays important roles
in the pathogenesis of AIP. ALA, in particular, has been implied to be
the causative agent in acute neurovisceral attacks and neurological
Figure 4. The Effect on ALA/PBG Excretion of the Hit
Compound and Analog in Hmbs-Deficient Mice
Three groups of Hmbs-deficient T1/T2/ mice (n = 6 in
each group) were treated for 12 days with 20 mg/kg/day of
C5, C6, or the analog C6-3, given orally. I.p. injection of
phenobarbital was given on days 10–12 to induce the heme
biosynthesis and thus, precipitation of biochemical acute
attack. The control group was given 10% DMSO and like-
wise induced with phenobarbital. Urine was collected on
days 1 and 10–12, and livers were harvested after sacrifice.
(A and B) Bars represent porphyrin precursors ALA (A) and
PBG (B) from C5 (red), C6 (blue), and C6-3 (green) treat-
ment, measured in the urine (u) pooled for all mice from each
group. The control group is shown in white. (C) HMBS
protein levels measured in liver lysates by western blot
quantification. Scatterplots with mean representing HMBS
protein levels in mice livers treated with C5 (red), C6 (blue),
and C6-3 (green). *p < 0.05 for differences with the corre-
sponding control (10% DMSO without compound; white
circles), calculated by unpaired two-tailed t test. Data are
presented as mean ± SD. (D) HMBS activity in liver lysates.
Scatterplot with mean showing the hepatic HMBS activity
after treatment with C6 (blue) and C6-3 (green). **p < 0.01
and ****p < 0.0001 for differences with the corresponding
control (10% DMSO without compound; white circles),
calculated by unpaired two-tailed t test. Data are presented
as mean ± SD. (E and F) The relative concentrations of ALA
(E) and PBG (F) were measured in liver tissue extracts after
treatment with C6 (blue) and C6-3 (green). *p < 0.05 for
differences with the corresponding control (10% DMSO
without compound; white), calculated by unpaired two-
tailed t test. Data are presented as mean ± SD.
www.moleculartherapy.orgsymptoms.51 A decrease in ALA and PBG excretion in urine is a
typical sign of successful treatment of patients with AIP symptoms,
and patients with chronically high levels of these metabolites present
normal ALA/PBG excretion following liver transplantation.52,53
In this work, we administered compounds to an Hmbs-deficient
T1/T2/ mouse model that exhibits residual expression of 30%
from the low-expressed normal allele. After phenobarbital induction,
the mice biochemically mimic an acute attack of AIP, showing
increased urinary ALA and PBG levels.33 Hmbs-deficient mice,Moltreated with either C6 or C6-3 before and during
the challenge of heme biosynthesis with pheno-
barbital, resulted in an increase in steady-state
levels of HMBS protein and activity, although a
substantial decrease of porphyrin precursors in
the liver was only measured for mice treated
with C6 (Figures 4A, 4B, 4E, and 4F). Impor-
tantly, as the HMBS expressed in the mice model
originates from the low-expressed normal allele,
these hit compounds and notable C6 show poten-
tial to be developed into a large-spectrum PC
medication that can operate on WT-HMBS
in vivo and function for most AIP patients regard-
less of their mutation. Still, it is expected that the
PCs would have a generalized stabilizing effect for
many HMBS variants, especially those mutantswith increased instability compared with WT, such as R116W and
V215E, among others.34
HMBS is a dynamic protein where loops and possible interdomain
flexibility accommodate the tetrapyrrole assembly with the
enzyme,42,54,55 and intermediate complexes are being formed during
the elongation. These intermediate states are present in vivo and also
in the recombinant purified HMBS protein as an equilibrium of the
states and may possess various formation rates with slightly differentecular Therapy Vol. 28 No 2 February 2020 683
Molecular Therapyconformations and stability.56 In our work with WT-HMBS, we did
not isolate the intermediates; however, PCs may be more effective to-
ward specific intermediate states. Although the docking to the ES2
structure did not reveal other favorable binding pockets, it cannot
be ruled out that the intermediate reaction state and formation rate
of HMBS will play a role in the binding of PCs. Furthermore, as
HMBS is monomeric, and allosterism has not been previously re-
vealed, the sigmoidal binding curve for C6 and C6-3 might be ex-
plained by the presence of conformation ensembles in this enzyme.
At least two classes of PCs have been described: (1) active site-specific,
also called classical PCs, and (2) non-active site PCs.49,57 The non-
active site PCs hold the same stabilizing abilities as the active site-spe-
cific and in some cases, show allosteric activating function.58,59
Allosteric compounds may induce a more active conformation, as
they can be bound to the target enzyme during catalysis without inhib-
iting activity.60 The structure of HMBS clearly presents cavities that
potentially can accommodate small molecular compounds, and the
molecular docking supports the binding of the hit compounds at a
pocket close to the active site, with a preferred binding to the sub-
strate-bound HMBS compared to the free enzyme, due to proper
orientation of Arg195 during catalysis. Arg195 is an important residue
for HMBS activity61,62 that is also in direct contact with the cofactor.55
Furthermore, Leu238 is identified as a hinge residue, and the com-
pound hits may also stabilize a catalytically favorable conformation
through this residue, perhaps with an allosteric effect. Despite the
good conformity of the protein-ligand-binding modes, the docking
structuresmust be interpreted with caution and ultimately be validated
experimentally.
In conclusion, we provide proof of concept of PC therapy for AIP by
in vivo experiments in Hmbs-deficient T1/T2/ mice, based on C6.
Allosteric inhibition of HMBS by protoporphyrinogen and copropor-
phyrinogen has been implicated on the mechanism of acute attacks in
variegate porphyria and hereditary coproporphyria,63 and it is
tempting to propose that this PC might be beneficial in the treatment
of other acute porphyrias as well. Furthermore, this work adds to the
recently discovered applicability of a PC-based therapy for congenital
erythropoietic porphyria.26 The expression of WT-HMBS from the
normal allele, providing half-normal protein levels and activity in
most AIP individuals, is advantageous in the development of PC ther-
apy for AIP, regardless of mutation, as we show the possibility of an
additionally increased stability and activity of the common WT-
HMBS.24,28–30 In addition, it is assumed that the half-normal activity
of HMBS is usually sufficient, and even a modest improvement of the
enzymatic activity could be adequate in order to avoid phenotypic
outcome,15 as has also been suggested for lysosomal storage en-
zymes.25 PC therapy may also possess advantages compared with
gene and RNAi therapies, such as orally administered treatment, re-
sulting in no immunological reactions, and could be applied as both a
prophylactic treatment and an intervention treatment during acute
porphyria attacks. As many drugs are known to induce the rate-
limiting ALAS,64 the predicted way forward to a successful hit expan-
sion and lead optimization, previous to structured toxicity analyses684 Molecular Therapy Vol. 28 No 2 February 2020for selection of the best drug candidate to enter clinical trials, should
include analyses of porphyrogenicity and derivatization of potential
porphyrinogenic compounds into less toxic versions through medic-
inal chemistry.63 In addition, further chemical efforts for rational hit-
to-lead amplification and optimization, development of treatment
protocols, and investigation of absorption, distribution, metabolism,
and excretion (ADME)/pharmacokinetics (PK) parameters for the
compounds will help to demonstrate the potential of PC therapy
for AIP.
MATERIALS AND METHODS
Materials and Structure Validation of Hit Compounds
TheMyriaScreen Diversity Collection (Sigma-Aldrich, St. Louis, Mis-
souri), a small compound library was used to screen for hit com-
pounds. It consists of 10,000 drug-like compounds at 2 mg/mL in
100% DMSO, with an average purity of 95%. The MW of the com-
pounds varies from 220 to 547 Da. Hit compounds were subsequently
obtained from MolPort (Vitas-M Chemical, Causeway Bay, Hong
Kong, and Alinda Chemical, Moscow, Russia), dissolved in 100%
DMSO, and stored at 20C. The chemical structure of all hit com-
pounds was confirmed by nuclear magnetic resonance (NMR).
Expression and Purification of HMBS Proteins
WT-HMBS were expressed and purified to apparent homogeneity, as
previously described,34 except for the enzyme used in the binding as-
says using the Octet RED96, which was expressed using a new
construct with an N-terminal 6histidine affinity tag and a tobacco
etch virus (TEV) protease cleavage site, for which full-length HMBS
was cloned into the pET-28a(+)-TEV vector and transformed into
BL21 (DE3) cells for expression. Expression was performed using
Terrific Broth medium with isopropyl b-D-1-thiogalactopyranoside
(IPTG) induction for 16 h at 20C with 220 rpm shaking. After har-
vesting, the cells were lysed with sonication, and purification was per-
formed by Ni-nitrilotriacetic acid (NTA) affinity chromatography.
The protein was eluted with 20 mM HEPES, 150 mM NaCl (pH 8),
supplemented with 400 mM imidazole. The affinity tag was cleaved
overnight and removed by Ni-NTA, and the protein was further pu-
rified by size-exclusion chromatography with a Superdex 75 10/300
GL or 16/60 PG column (GE Healthcare, Chicago, Illinois) in
20 mM HEPES, 150 mM NaCl (pH 8 or 8.0), respectively, and stored
in aliquots in liquid N2 until use.
High-Throughput Screening of Ligands Binding to HMBS
The thermal denaturation of recombinantWT-HMBS wasmonitored
with the fluorescent probe SYPRO Orange (Thermo Fisher Scientific,
Waltham, Massachusetts) in the search for stabilizing ligands among
the 10,000 compounds from the MyriaScreen Diversity Collection,
using DSF. The protocol for screening was as previously reported,28
but in this work, we used a protein solution of 0.1 mg/mL HMBS
in 20 mM Tris-HCl, 100 mM NaCl (pH 8.0), 5  SYPRO Orange,
and 0.04 mg/mL compound (averaged final concentration of
100 mM for all compounds in 2% DMSO). The samples were applied
into 96-well PCR plates (Roche Diagnostics, Risch-Rotkreuz,
Switzerland) and loaded into a Light Cycler 480 (Roche Diagnostics).
www.moleculartherapy.orgReferences with 2% DMSO without compounds were included on
each plate. Unfolding curves were recorded with 0.2C intervals
with a scan rate of 2C/min from 20C to 95C, and monitored at
excitation (lex) = 465 nm and emission (lem) = 610 nm. The exper-
imental unfolding curves were normalized to fraction of unfolded
protein (Fu) and smoothed using a Savitzky-Golay smoothing filter.
The original hits were selected based on the Tm value and extracted
from the fluorescence curves at the temperature where the scaled
curves cross y = 0.5, but because of the complexity of the curves
with several transitions, a qualitative inspection of each positive hit
was also performed, using both the Tm and the dF/dT. Compounds
that gave a positive DTm R 1.5C, providing a cutoff value of 3-
fold > SD for the Tm for DMSO controls in the screening, were
defined as hit compounds and selected for further analyses.
Enzymatic Activity Assay of HMBS
The standard enzymatic activity of recombinant WT-HMBS was as-
sayed in 50 mM HEPES (pH 8.2), 0.1% Triton-X, and 2% DMSO at
37C, as reported.34 Compounds were added at a concentration of
84 mM. The absorbance of uroporphyrinogen I was determined at
405 nm. The enzyme activity in the presence of compounds was
normalized relative to DMSO control (relative activity). The effect
of compounds on the stability of HMBS activity was assayed by prein-
cubating the HMBS (4–5 mg) in 50 mMHEPES (pH 8.2), 84 mM com-
pound, and 2% DMSO for 20 min at 70C and then placed on ice for
5 min. The enzymatic activity at 37C was subsequently measured as
reported.34 Controls without compound but with an equal concentra-
tion of DMSO were included. The remaining activity in the presence
of compounds was normalized relative to DMSO control (relative
activity). KM and Vmax were determined using an increasing concen-
tration of PBG (3.125–1,000 mM), and the kinetic parameters were ob-
tained by nonlinear fitting toMichaelis-Menten enzyme kinetics using
GraphPad Prism version 8.2.0 for Windows (GraphPad Software, La
Jolla, California, USA; https://www.graphpad.com/).
To assay the HMBS activity in liver lysates, the crude liver homoge-
nates were passed through Zeba spin desalting columns (Thermo
Fisher Scientific) using 50mMHEPES (pH 8.2) as equilibration buffer.
25 mL filtrated homogenate (400–500 mg total protein) was added to
110 mL sample mix (50 mM HEPES [pH 8.2], 1% Triton X-100) and
incubated for 10min at 37C before adding PBG (1mM). The reaction
was stopped after 1 h by adding ice-cooled 100% trichloroacetic acid
(TCA) to a final concentration of 25%, incubated at room temperature
(RT) for 10 min, and centrifuged at 10,000 g for 10 min. The absorp-
tion was measured in the supernatant at A409 with baseline correction
at A380 using the NanoDrop 2000c spectrophotometer (Thermo Fisher
Scientific). The activity of HMBS was expressed as relative activity in
the compound-treated cell compared to DMSO controls. A blank sam-
ple was prepared for each homogenate. The unpaired t test (two-tailed)
was performed using GraphPad Prism.
Limited Proteolysis by Trypsin
Limited proteolysis by trypsin was performed at 37C in 20 mM
HEPES, 150 mM NaCl, 2% DMSO (pH 8.2), with 0.15 mg/mLHMBS in the absence (DMSO control) or presence of 84 mM com-
pound and 2% DMSO. The proteolysis was initiated by adding
1 mg/mL N-tosyl-L-phenylalanine chloromethyl ketone (TPCK)-
treated trypsin (Sigma-Aldrich). After 30 min, aliquots were removed
and transferred to Laemmli loading buffer containing 2 mg/mL soy-
bean trypsin inhibitor. Samples resolved by SDS-PAGE with 10%
Mini-Protean TGX gels (Bio-Rad Laboratories, Hercules, California)
were analyzed using the Image Lab software (Bio-Rad). The unpaired
t test (two-tailed) was performed using GraphPad Prism.
Transfection of HepG2 Cells and Growth in the Presence of
Compounds
The human hepatoma HepG2 cells were obtained from Leibniz-Insti-
tut DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkul-
turen. Cells were maintained in RPMI 1640, GlutaMAX (Thermo
Fisher Scientific) medium, supplemented with 10% heat-inactivated
fetal bovine serum and 1% penicillin-streptomycin (Thermo Fisher
Scientific) in a humidified incubator with 5% CO2 at 37C. HMBS
cDNA was inserted into the pcDNA3.1(+) cloning vector (Thermo
Fisher Scientific). The HepG2 cells were then transfected with the
pcDNA3.1(+) vector containing HMBS using FuGENEHD Transfec-
tion Reagent (Promega, Madison, Wisconsin), according to the man-
ufacturer’s recommendations. Stably transfected clones were selected
for resistance to the neomycin analog G418 (Thermo Fisher Scienti-
fic). WT-HMBS-transfected HepG2 cells (2  106) were seeded and
grown for 22 h before compounds were added to final concentrations
of 0, 40, 84, 120, and 168 mM in 2% DMSO. Cells were harvested after
24 h and analyzed as described below.
SPR
SPR experiments for the estimation of the concentration of com-
pound at S0.5 were performed using a Biacore T200 (GE Healthcare)
instrument at 25C. 150 mg/mLWT-HMBS in 10 mM sodium acetate
(pH 4.5) was immobilized onto a CM5-S sensor chip through amine-
coupling chemistry and PBS containing 0.05% surfactant P20 as the
running buffer, reaching immobilization levels15,000. The baseline
was equilibrated for 1–2 h before C6 and C6-3 were assayed in a con-
centration-dependent manner (0–200 mM) using running buffer with
5% DMSO and 30 mL/min flow rate. Contact and dissociation time
was 60 s, with a final wash after 50% DMSO injection. Blank immo-
bilization, solvent correction, and negative control (assay buffer) were
included for the analysis of the sensorgrams using the Biacore T200
Evaluation software v2.0. The allosteric sigmoidal curve fitting was
performed using GraphPad Prism.
Octet RED96
Octet RED96 system (FortéBio Biologics by Molecular Devices, San
Jose, California) with super streptavidin (SSA) biosensors was used
as an additional method for determining the binding affinity of C6.
The loading of HMBS to the SSA sensors required biotinylation,
which was carried out at room temperature, mixing 1.5 molar excess
of N-hydroxysuccinimide (NHS)-ester biotinylation reagent (EZ-
Link NHS-PEG4-Biotin; Thermo Fisher Scientific) to protein. After
30 min, excess of biotin was removed using Zeba spin desaltingMolecular Therapy Vol. 28 No 2 February 2020 685
Molecular Therapycolumns (Thermo Fisher Scientific), and the gel filtration buffer was
changed to reaction buffer, PBS-P+ (GE Healthcare), supplemented
with 5% DMSO. Sensors were loaded with 5 mg/mL of biotinylated
HMBS, reaching 6 nm surface thickness. Triplicates for the concen-
tration series of C6 were measured, and double-reference subtraction
was applied for data analysis based on the steady-state kinetics with
an equilibrium binding signal (Req) using ForteBio Data analysis
9.0. The allosteric sigmoidal curve fitting was performed using Graph-
Pad Prism.
Animal Studies
The compound heterozygote Hmbs-deficient T1/T2/ mouse
model33 was utilized in the two sets of animal studies performed,
T1/T2-A and T1/T2-B: (1) in the T1/T2-A study, mice (2–4 months
old, 16–22 g) were given 10 mg/kg/day of either compound C5 or C6;
(2) in the T1/T2-B study, mice (2–3months old, 17–22 g) were treated
with 20 mg/kg/day of hit compound C5 and C6 and analog C6-3. The
mice in both groups were given phenobarbital (Gardenal) at
100 mg/kg through intraperitoneal (i.p.) injection on days 10–12 of
the study. Urine from these mice was collected on day 1 before the
start of treatment and each day of phenobarbital injection (days 10,
11, and 12). The protocol is presented in Figure S2.
Compounds were dissolved in 10% DMSO, and all studies included
treatment groups with six mice in each, including a control group
given only 10%DMSO. The compounds or DMSO alone were admin-
istered orally for 12 consecutive days, and the mice were sacrificed
30 min after the last dose of compound or phenobarbital. The mice
were anaesthetized by i.p. injection of tribromoethanol (3 mg/kg),
blood samples collected on EDTA by retro-orbital puncture, and
livers harvested and flash frozen in liquid N2 before storage at
80C. Pooled urinary porphyrin precursor levels (ALA and PBG)
were analyzed by sequential ion-exchange chromatography using
the ALA/PBG by Column Test (Bio-Rad), according to the manufac-
turer’s recommendations.
Study Approval
All animal experiments were performed according to procedures
approved by the Bichat-Debré Ethics Committee. Animals were
housed in a controlled environment with a 12-h light-dark photo-
cycle, with free access to water and food.
Cell and Tissue Sampling
HepG2 cells were washed in ice-cold PBS before 10 min lysis on ice
with cold radioimmunoprecipitation assay (RIPA) buffer (25 mM
Tris-HCl, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 1% sodium
deoxycholate, 0.1% SDS [Cell Signaling Technologies, Danvers,
Massachusetts] and cOmplete protease inhibitor cocktail [Roche Di-
agnostics]). Lysates were centrifuged (10,000 g, 4C, 15 min), and su-
pernatants were removed and stored at 80C until further use.
Frozen liver tissue was homogenized in 50 mM Tris-HCl (pH 7.4),
100 mM KCl, 1 mM DTT, 0.2 mM PMSF, 1 mM benzamidine,
1 mM EDTA, and 1 tablet/10 mL cOmplete ULTRA protease inhib-
itor cocktail (Roche Diagnostics) using TissueLyser II (QIAGEN,686 Molecular Therapy Vol. 28 No 2 February 2020Venlo, Netherlands). The extracts were clarified by centrifugation at
14,000 g for 20 min at 4C, and supernatants were stored at 80C.Quantitative Detection of HMBS in Cell Lysate and Tissue by
Immunoblot
Cell lysate samples (20 mg total protein) were separated by electropho-
resis and subsequently transferred to a polyvinylidene difluoride
(PVDF) transfer membrane (Bio-Rad). Membranes were blocked
for 1 h at RT with 5% nonfat dry milk (Bio-Rad Laboratories) in
Tris-buffered saline (TBS; 20 mm Tris-HCl, 140 mM NaCl [pH
7.4]), containing 0.1% Tween (0.1% TBS-T). Immunoblotting was
carried out with 1:1,000 anti-HMBS primary antibody (Ab; H300;
Santa Cruz Biotechnology, Dallas, Texas) in 0.1% TBS-T overnight
at 4C. Subsequently, the membranes were washed extensively in
0.1% TBS-T, followed by 1 h incubation at RT with horseradish
peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G
(IgG) secondary Ab (Bio-Rad), 1:5,000 dilution. Anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH; Abcam, Cambridge, UK) was
used as a loading control. Chemiluminescence of secondary Ab-HRP
conjugates was elicited using Luminata Crescendo Western HRP
Substrate (Merck Millipore, Burlington, Massachusetts), imaged
with Gel Doc XR+ (Bio-Rad), and quantified using Image Lab soft-
ware (Bio-Rad).
Liver homogenates (5 mg total protein/lane) were loaded onto 10%
Mini-Protean TGX gels (Bio-Rad) and separated with Tris/glycine/
SDS electrophoresis buffer (Bio-Rad). Trans-Blot Turbo Transfer
Starter System (Bio-Rad) was used to transfer the proteins onto Im-
mun-Blot low-fluorescence PVDF membranes (Bio-Rad). The mem-
branes were then blocked with 1% TBS-T and 3% BSA for 1 h. HMBS
was probed with 1:2,000 monoclonal mouse anti-HMBS (H-11; Santa
Cruz Biotechnology), together with 1:1,000 rabbit anti-actin (Sigma-
Aldrich), in 1% TBS-T, 3% BSA overnight, 4C. Alexa Fluor 647-con-
jugated donkey anti-mouse and Alexa Fluor 488-conjugated donkey
anti-rabbit (both Thermo Fisher Scientific) were used as secondary
antibodies and incubated in 1:1,000 dilutions in 0.1% TBS-T for 1
h. Each step was followed by extensive washing with 0.1% TBS-T.
Fluorescence detection was performed using G-Box Chemi-XRQ
(Syngene Synoptics, Cambridge, UK) with filters UV06 and 705 nm
for AF-488 and AF-647, respectively, and the band intensities of
HMBS relative to the loading control (GAPDH) were determined us-
ing ImageJ.65 Plotting and the unpaired two-tailed t test were per-
formed using GraphPad Prism version 8.2.0.Derivatization of C6
A similarity search of C6 was performed over the MolPort libraries
(https://www.molport.com/shop/index) of commercially available
compounds.66 The libraries were downloaded from the ZINC data-
base, and Tanimoto coefficients38 to the query compounds were
calculated for the 2D molecular similarity using OpenBabel and the
ChemInf packages.39 All compounds showing a Tanimoto coefficient
of more than 70% to the query compounds were collected and clus-
tered based on their pairwise similarity.
www.moleculartherapy.orgProtein-Ligand Docking
Identification of pockets on the surface of HMBS and possible binding
sites were probed with fpocket41 using the structure with PDB:
3ECR55 or 5M6R42 as input. Docking of C6 and C6-3 to the identified
pockets was performed with Glide (Schrödinger, New York, NY)67
using default settings for ligand and protein preparation, grid gener-
ation, and docking.
Determination of Metabolites in Liver Tissue Samples
One volume of homogenized liver tissue was mixed with two volumes
of acetonitrile:MetOH (1:1, v/v) and centrifuged. High-performance
liquid chromatography/tandem mass spectrometry (HPLC-MS/MS)
was used to determine the concentration of ALA and PBG in the su-
pernatants. Analyses of samples were conducted by the Bioanalytical
Laboratory personnel at Enamine/Bienta (Bienta/Enamine Biology
Services, Kiev, Ukraine; http://bienta.net/). The unpaired t tests
(two-tailed) were performed using GraphPad Prism version 8.2.0.
Statistics
Results are presented as mean ± SD. Statistical comparisons were
done using unpaired two-tailed t test, and statistical significance
was defined as p < 0.05 or lower, as specified in the text. All statistical
analyses and plotting of data were performed in GraphPad Prism
8.2.0.
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Table S1. Overview of the 13 primary hit compounds. 































C24 2-[(1,3-Benzodioxol-5-ylamino)methyl]-4-bromophenol 4.27 322.16 
aLogP describes the logarithm of the partition coefficient between n-octanol and water log(coctanol/cwater), 




Figure S1. Effect of hit compound C5, C11 and C17 on HMBS levels in HepG2 cells. The 
western blots show the immunodetection of HMBS and GAPDH (loading control) in lysates 
from WT-HMBS transfected HepG2 cells after treatment with C5, C11 or C17 at the 
indicated concentrations. See main text for further details. Std, molecular weight standards at 




Figure S2: Schematic protocol followed in mice trials. Female compound heterozygote 
Hmbs-deficient T1/T2−/− mice (n=6 per group) were kept on normal diet and given 10 or 20 
mg/kg/day (trial T1/T2-A and T1/T2-B, respectively) of either hit compounds or DMSO, by 
oral gavage, for 12 consecutive days. Biochemical acute attack was induced by intraperitoneal 
injection of phenobarbital days 10–12. Urine was collected on day 1 and 10–12, and blood 




Figure S3: Effect of the hit compounds C5 and C6 in Hmbs−/− mice (trial T1/T2-A). Two 
groups of Hmbs T1/T2−/− mice (n=6 in each group) were orally treated for 12 days with 10 
mg/kg/day of C5 and C6. On day 10, 11 and 12 they were induced by phenobarbital. A 
control group (n=6) was given 10% DMSO, and likewise induced with phenobarbital. On 
days 1 and 10–12 urine was collected and pooled from each group before measurement. See 
Fig. S2 for schematic presentation of treatment protocol. (A, B) Bars represent porphyrin 






Figure S4: Concentration-dependent surface plasmon resonance. (A,B) Representative 
original sensorgrams with the increase of concentration of either C6 (A) or C6-3 (B), up to 





Figure S5: The interaction of C6 and C6-3 with HMBS reaction intermediate ES2. The 
structure of HMBS in the ES2 state (PDB ID: 5M6R) provided overlapping pockets as in the 
holoenzyme, and is shown in cartoon representation with cyan surface representing the 
pockets. The DPM cofactor with two additional substrates are visualized in green and red 
spheres. (A,B) Top-score docking modes for C6 (blue and orange sticks; A) and C6-3 (pink 
and yellow sticks; B).  
 
 
 
